Baseline demographics by the presence or absence of anemia
. | . | Anemia, Hb less than 110 g/L . | . | Anemia, WHO criteria* . | . | ||
|---|---|---|---|---|---|---|---|
| Characteristic . | Total¶ . | Absent† . | Present‡ . | Absent§ . | Present∥ . | ||
| Mean age, y (SD) | 74.9 (6.3) | 74.8 (6.4) | 77.7 (7.1) | 74.6 (6.3) | 77.3 (7.0) | ||
| 66 to 70, % | 5100 (30.0) | 30.3 | 19.5 | 31.5 | 19.9 | ||
| 71 to 75, % | 4903 (28.8) | 29.2 | 20.6 | 29.5 | 24.0 | ||
| 76 to 80, % | 3618 (21.2) | 21.2 | 24.2 | 21.0 | 23.1 | ||
| 81 to 85, % | 2148 (12.6) | 12.2 | 22.5 | 11.5 | 19.8 | ||
| Older than 85, % | 1261 (7.4) | 7.2 | 13.2 | 6.5 | 13.1 | ||
| Female, % | 9471 (55.6) | 55.2 | 64.0 | 56.3 | 51.4 | ||
| Male, % | 7559 (44.4) | 44.8 | 36.0 | 43.7 | 48.6 | ||
| Estimated GFR, % | |||||||
| Normal, GFR of 60 | 12 871 (75.6) | 77.0 | 43.7 | 79.3 | 50.5 | ||
| Stage 3, GFR 30 to 59 | 3694 (21.7) | 21.0 | 37.4 | 19.4 | 37.2 | ||
| Stages 4 and 5, GFR less than 30 | 465 (2.7) | 2.0 | 18.9 | 1.3 | 12.4 | ||
| Diabetes, % | 2278 (13.4) | 12.9 | 23.2 | 11.8 | 24.2 | ||
| Comorbidity score, median (IQR) | NA | 2134 (1496-3044) | 3299 (2293-4473) | 2075 (1460-2933) | 3057 (2152-4139) | ||
| Erythropoietin-stimulating protein use, % | 69 (0.4) | 0.3 | 2.6 | 0.2 | 1.7 | ||
. | . | Anemia, Hb less than 110 g/L . | . | Anemia, WHO criteria* . | . | ||
|---|---|---|---|---|---|---|---|
| Characteristic . | Total¶ . | Absent† . | Present‡ . | Absent§ . | Present∥ . | ||
| Mean age, y (SD) | 74.9 (6.3) | 74.8 (6.4) | 77.7 (7.1) | 74.6 (6.3) | 77.3 (7.0) | ||
| 66 to 70, % | 5100 (30.0) | 30.3 | 19.5 | 31.5 | 19.9 | ||
| 71 to 75, % | 4903 (28.8) | 29.2 | 20.6 | 29.5 | 24.0 | ||
| 76 to 80, % | 3618 (21.2) | 21.2 | 24.2 | 21.0 | 23.1 | ||
| 81 to 85, % | 2148 (12.6) | 12.2 | 22.5 | 11.5 | 19.8 | ||
| Older than 85, % | 1261 (7.4) | 7.2 | 13.2 | 6.5 | 13.1 | ||
| Female, % | 9471 (55.6) | 55.2 | 64.0 | 56.3 | 51.4 | ||
| Male, % | 7559 (44.4) | 44.8 | 36.0 | 43.7 | 48.6 | ||
| Estimated GFR, % | |||||||
| Normal, GFR of 60 | 12 871 (75.6) | 77.0 | 43.7 | 79.3 | 50.5 | ||
| Stage 3, GFR 30 to 59 | 3694 (21.7) | 21.0 | 37.4 | 19.4 | 37.2 | ||
| Stages 4 and 5, GFR less than 30 | 465 (2.7) | 2.0 | 18.9 | 1.3 | 12.4 | ||
| Diabetes, % | 2278 (13.4) | 12.9 | 23.2 | 11.8 | 24.2 | ||
| Comorbidity score, median (IQR) | NA | 2134 (1496-3044) | 3299 (2293-4473) | 2075 (1460-2933) | 3057 (2152-4139) | ||
| Erythropoietin-stimulating protein use, % | 69 (0.4) | 0.3 | 2.6 | 0.2 | 1.7 | ||
NA indicates not applicable.
Hemoglobin than 130 g/L in males and less than 120 g/L in females
n = 16 311, 95.8% of the total.
n = 719, 4.2% of the total.
n = 14 812, 87.0% of the total.
n = 2218, 13% of the total.
Numbers in parentheses in this column are percentages; those outside parentheses represent total n.